Does Rallies show Form 4 insider transactions for OPK?

Yes. Rallies tracks OPK insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is OPK research on Rallies investment advice?

No. Rallies provides research, data, and educational context for OPK. It does not provide personalized investment advice.

OPK (Opko Health Inc.) Stock Analysis - Insider Trades

Opko Health Inc. (OPK) is a publicly traded Healthcare sector company. As of May 21, 2026, OPK trades at $1.24 with a market cap of $853.25M and a P/E ratio of -4.50. OPK moved +7.83% today. Year to date, OPK is -3.91%; over the trailing twelve months it is -7.52%. Its 52-week range spans $0.98 to $2.04. Analyst consensus is strong buy with an average price target of $3.00. Rallies surfaces OPK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading OPK stock inside the company?

Recent OPK insider activity includes PAGANELLI JOHN A bought 10.00K, FROST PHILLIP MD ET AL bought 102.37K, FROST PHILLIP MD ET AL bought 3.89K, FROST PHILLIP MD ET AL bought 89.38K, and FROST PHILLIP MD ET AL bought 191.49K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

OPK Key Metrics

Key financial metrics for OPK
Metric	Value
Price	$1.24
Market Cap	$853.25M
P/E Ratio	-4.50
EPS	$-0.27
Dividend Yield	0.00%
52-Week High	$2.04
52-Week Low	$0.98
Volume	12
Avg Volume	0
Revenue (TTM)	$581.12M
Net Income	$-212.91M
Gross Margin	35.98%

Recent OPK Insider Trades

PAGANELLI JOHN A bought 10.00K (~$11.35K) on Mar 20, 2026.
FROST PHILLIP MD ET AL bought 102.37K (~$133.08K) on Nov 21, 2025.
FROST PHILLIP MD ET AL bought 3.89K (~$5.14K) on Nov 21, 2025.
FROST PHILLIP MD ET AL bought 89.38K (~$118.42K) on Nov 21, 2025.
FROST PHILLIP MD ET AL bought 191.49K (~$254.68K) on Nov 21, 2025.

Latest OPK News

ModeX to Reveal MDX3001 In Vivo CAR-T Generation and Deep B-Cell Depletion Data — May 12, 2026
OPKO Health Takes 15% Equity Stake in Nicoya for China RAYALDEE Expansion — Apr 30, 2026
OPKO Health Q1 Loss Improves to $54.8M; Diagnostics Breakeven by Mid-Year — Apr 29, 2026
OPKO Health Launches Phase 1 Trial for MDX2301 COVID-19 Antibody in 80 Adults — Apr 8, 2026
OPKO Health Beats Q4 Estimates with $148.5M Revenue, Guides $125M–$140M Q1 — Feb 27, 2026

OPK Analyst Consensus

4 analysts cover OPK: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $3.00.

Common questions about OPK

Who is trading OPK stock inside the company?: Recent OPK insider activity includes PAGANELLI JOHN A bought 10.00K, FROST PHILLIP MD ET AL bought 102.37K, FROST PHILLIP MD ET AL bought 3.89K, FROST PHILLIP MD ET AL bought 89.38K, and FROST PHILLIP MD ET AL bought 191.49K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for OPK?: Yes. Rallies tracks OPK insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is OPK research on Rallies investment advice?: No. Rallies provides research, data, and educational context for OPK. It does not provide personalized investment advice.